TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04261218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tomivosertib
Description: Tomivoserib is supplied as a 100 mg capsule, to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tomivosertib
Description: Tomivoserib is supplied as a 100 mg capsule, to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Taken weekly according to the current market label in combination with experimental tomivosertib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Taken weekly according to the current market label in combination with experimental tomivosertib.
Study: NCT05255497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex Balance Exercise System
Description: Patients in the intervention group (n=14) performed exercises using the computerized BBS. The control group (n=13) was just informed about diabetes self-management.
Study: NCT01818765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-ventricular-septal placement of LV pacing lead

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-procedure speckle-tracking echocardiography
Description: Assessment of site of latest mechanical activation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute response assessment
Description: Cardiac output monitoring
Study: NCT00860704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluidotherapy with ringer-lactate
Description: a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluidotherapy with ringer-lactate
Description: a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluidotherapy with ringer-lactate
Description: a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
Study: NCT02630394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Study: NCT04164849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid
Description: 5-aminolevulinic acid (30 mg/ml) will be added to mononuclear cells in a dose of 3 millimolar and incubated for 1 hour
Study: NCT02063022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy
Description: * Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks~* Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment~* Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)
Study: NCT03879226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBMT
Description: PBMT will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for the applications during the training and/or detraining periods will be 30 Joules (J) per site (510 J per lower limb). PBMT will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
Study: NCT04164849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blue light photopheresis
Description: The mononuclear cells incubated with 5-aminolevulinic acid for 1 hour will be exposed to blue light.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: The treated cells are transferred back to the patient as a standard blood transfusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Mononuclear Cell Collection (CMNC)
Description: The mononuclear cells are collected using the Spectra Optia with the Continuous Mononuclear Cell Collection protocol. 90 ml of mononuclear cells will be collected and 100 ml of 0,9% saline will be added to dilute the cells before incubation with drug and photopheresis.
Study: NCT01908049

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04343391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief transdiagnostic cognitive-behavioral therapy
Description: Time-limited transdiagnostic evidence-based psychological treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief transdiagnostic cognitive-behavioral therapy
Description: Time-limited transdiagnostic evidence-based psychological treatment
Study: NCT01923493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tuina
Description: Patients in the tuina group will receive a tuina therapy (also known as Chinese massage). A Chinese massage lasts about 20 to 30 minutes. A series of 6 sessions with 2 treatments per week is applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no intervention
Description: Patients in the no intervention waiting list group will not receive a study intervention. They will continue their respective pre-study therapy during the study period.
Study: NCT02740764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimization of drug prescribing
Description: The patients included in this group will have the intervention. The optimization of drug prescribing consists to a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital and sent to the referring physicians of patients, who can accept or not the recommendations.
Study: NCT01202474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous Dose regimen: 0-15 minutes before meal or within 20 minutes from the start of meal according to prandial plasma glucose values
Study: NCT04343391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological treatment
Description: Treatment as usual in PC
Study: NCT01630577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: volume expansion using modified gelatin
Description: Volume expansion using modified gelatin was determined according to a procedure formulated by modifying guidelines produced by Weil and Henning. The maximum volume infusion during the study test was fixed at 400 ml.
Study: NCT03490760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg (or 20 mg/m2 if \<30 kg) IV every 4 weeks
Study: NCT04226144

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breath Stacking Group
Description: Lung recruitment technique using manual bag resuscitation with oronasal mask interface
Study: NCT00609297

Intervention type: OTHER
Intervention: medical chart review
Description: The Research Nurse will conduct a chart review after the patient's death.
Study: NCT03944460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contraloid
Description: Oral administration of capsules, drug substance or placebo without any excipients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contraloid
Description: Oral administration of capsules, drug substance or placebo without any excipients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contraloid
Description: Oral administration of capsules, drug substance or placebo without any excipients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contraloid
Description: Oral administration of capsules, drug substance or placebo without any excipients.
Study: NCT00609297

Intervention type: OTHER
Intervention: questionnaire administration
Description: The questionnaires will be completed at the end of week 1, week 2 and week 4.

Intervention type: OTHER
Intervention: survey administration
Description: Given to patient and caregivers throughout the study
Study: NCT04226144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath stacking and EMT
Description: Lung recruitment technique with one way valve with counter resistance during all expiratory phase
Study: NCT02233608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Pelvic Floor Muscle Exercise (APFX)
Study: NCT01207804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ValenTx Endo Bypass System
Description: Patient is implanted with device and followed for 12 weeks
Study: NCT01347073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-100
Description: HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (\~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
Study: NCT01728649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild Hypothermia
Description: Hypothermia will be achieved using the Zoll Thermoguard XP technology with the Quattro catheter. This catheter has a 9.3 Fr diameter and is 4 3cm long. It will be placed in the patients femoral vein via Seldinger technique, before reperfusion is achieved. Hypothermia will be initiated prior to reperfusion. Once temperature has reached 33.5 degrees centigrade the patient will remain at that temperature for 12 hours after which the patient will undergo active gradual rewarming at 0.2 degrees centigrade per hour.
Study: NCT03944460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contraloid
Description: Oral administration of capsules, drug substance or placebo without any excipients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Contraloid
Description: Oral administration of capsules, drug substance or placebo without any excipients.
Study: NCT01467128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured expert pharmacist review
Description: The researcher will apply the pharmacist intervention to the cases randomised to this arm of the study. This consists of an expert pharmacist review of the patients prescribed medications at the time of recruitment into the study. Recommendations following the intervention will be communicated both verbally and in writing to the medical team with primary responsibility for the patient. Recommendations arising from the intervention will be printed out and inserted into the patients' notes, in addition to the relevant registrar being informed in person or via the telephone.
Study: NCT00596349

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL- Cancer Survivor, FACT-Ovarian, SF-36, CES-D, IES, FACT-GOG-NTX, FSFI, Cognition Testing, Perception of disease chronicity/acuity, Report of surveillance type, frequency, utility, Health behaviors, Self-report of co-morbidities, Self-report of potential unmet needs, Background information form, List of current medications,Patient-defined QoL domains
Study: NCT02330601

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopic papillary large balloon dilation
Description: For the patients in EPLBD group, a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
Study: NCT06092840

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Transform Burn
Description: Study product Transform Burn contains dihydrocapsiate, red pepper (Capsicum annuum) fruit extract, citrus (Citrus spp) peel extract, coleus (Coleus forskholi) root extract, and african mango (Irvingia gabonensis) seed extract.
Study: NCT01467128

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No Intervention
Description: Normal hospital pharmaceutical care
Study: NCT02530190

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent pneumatic compression
Description: 20 minutes of intermittent pneumatic compression to lower extremities

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: massage
Description: 20 minutes of massage to lower extremities
Study: NCT03808844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Initial dose of 2.0 mg/kg followed by 1.0 mg/kg if needed
Study: NCT00822640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.
Study: NCT04801355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full-thickness laparo-endoscopic colon adenomas excision
Description: Full-thickness laparo-endoscopic removal of colon adenomas will be performed as follows: an endoscopist during intraoperative colonoscopy visualize the neoplasm, intra-luminary marks the margins of resection and stop at this in some cases. In another one: endoscopist start full-thickness removal of this lesion then the abdominal team during laparoscopy, with using laparoscopic technique, performe full-thickness resection of intestine wall with the tumor. Speciment extracted intralumenary or via minilaparotomy. Defect of the intestinal wall is sutured intracorporeally using laparoscopic technic. Desuflation, suturing of trocar sites.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic colon resection
Description: Standard laparoscopic colon resection
Study: NCT01599949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
Study: NCT02017067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hydraulic resistance circuit training
Description: 12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 7 types of equipments for different part of strength training.
Study: NCT03887325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxipost
Description: To investigate the role of maxipost on cerebral hemodynamic and headache in healthy volunteers and migraine patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
Study: NCT03621124

Intervention type: PROCEDURE
Intervention: Resting Energy Expenditure
Description: During each visit, the participant will be assessed in a resting state in a stable temperature controlled environment, and will undergo tests to find out how the body adjusts its metabolism to different temperatures.

Intervention type: PROCEDURE
Intervention: Resting Energy Expenditure
Description: During each visit, the participant will be assessed in a resting state in a stable temperature controlled environment, and will undergo tests to find out how the body adjusts its metabolism to different temperatures.
Study: NCT01189149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV fluids
Description: Infants will be allocated to IV fluids

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Naso/oro gastric tube feedings
Description: Infants will be allocated to naso/oro gastric tube feedings
Study: NCT03621124

Intervention type: OTHER
Intervention: Thermal Comfort Questionnaire
Description: Patients will be given a questionnaire to assess their thermal response (whether they felt warmer or colder) during each study visit.

Intervention type: OTHER
Intervention: Thermal Comfort Questionnaire
Description: Patients will be given a questionnaire to assess their thermal response (whether they felt warmer or colder) during each study visit.
Study: NCT05592444

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low iodine Spectral Detector CT Pulmonary Angiography
Description: Low iodine Spectral Detector CT Pulmonary Angiography
Study: NCT02572700

Intervention type: OTHER
Intervention: Clinical examination, blood sampling, ultrasonic assessment, and questionnaires
Description: Visits include clinical examination, questionnaires (pain, comorbidity, lifestyle, work status) and ultrasonography of joints and entheses, blood samples, and only at baseline x-ray of hands and feet.
Study: NCT04248244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HADS questionnaire
Description: HADS questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
Study: NCT00483054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: efavirenz 600 mg/day + stavudine + lamivudine
Study: NCT03490760

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
Study: NCT00620087

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Molecular Breast Imaging
Description: Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
Study: NCT03402854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active transcranial direct current stimulation
Description: Participants will receive 20 min of tDCS over the scalp during the first 20 min of bimanual training.
Study: NCT03402854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bimanual training
Description: Participants will engage in movements that use both hands, by playing with toys and games.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bimanual training
Description: Participants will engage in movements that use both hands, by playing with toys and games.
Study: NCT02766946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromyopathy score
Description: A neuromyopathy score will be assessed on the extubation day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromyopathy score
Description: A neuromyopathy score will be assessed on the extubation day
Study: NCT00676728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26481585
Description: In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle. Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
Study: NCT00483054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nevirapine
Description: nevirapine 400 mg/day + stavudine +lamivudine